MENLO PARK, Calif, Dec. 5, 2016 /PRNewswire/ -- BioPharmX
Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company
developing products for the dermatology and women's health markets,
will share research with the cell biology community next week that
identifies the mechanism of action by which molecular iodine can
fight fibrocystic breast condition (FBC)
The data will be shared in a poster presentation titled "The
Molecular Mechanism of Action of Molecular Iodine on MCF10A Cells
from Fibrocystic Breast Tissue," at the ASCB's Cell Biology 2016 in
San Francisco, Tuesday.
Results from the in vitro study indicated
that molecular iodine had potent inhibitory effects on
cell growth and showed an increase in the death MCF10A cells,
a human immortalized mammary epithelial cell line derived from
fibrocystic breast tissues. The study also found that molecular
iodine had no significant impact on healthy cells.
The study found that molecular iodine can induce cell death by
activating caspase-independent apoptosis.
"The administration of molecular iodine to patients with FBC
reduces swelling and other FBC symptoms," said Lee P. Shulman MD, Professor of Ob/Gyn at the
Feinberg School of Medicine of Northwestern
University in Chicago,
Illinois. "The results indicate that iodine inhibits
proliferation of MCF10A cells in vitro, suggesting a potential
mechanism of action for molecular iodine in the treatment of
symptoms of FBC.
Iodine supplementation has long been recognized in clinics for
the treatment of symptoms experienced by patients with FBC, a
condition estimated to affect approximately 50 percent of women.
Symptoms of FBC include breast swelling, pain, and
tenderness. This study is the first to identify molecular
iodine's mechanism of action on fibrocystic breast tissue-derived
cells.
BioPharmX, Inc., has developed a novel and proprietary
formulation sold as Violet® iodine, which consists of iodide and
iodate salts that, when exposed to gastric pH, react to form
molecular iodine.
About BioPharmX® Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based
specialty pharmaceutical company that seeks to provide products
through proprietary platform technologies for prescription,
over-the-counter and supplement applications in dermatology and
women's health. To learn more about BioPharmX, visit
www.BioPharmX.com.
Forward-Looking Statement
The information in this press release contains forward-looking
statements and information within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, which are subject to
the "safe harbor" created by those sections. This press release
contains forward-looking statements about the company's
expectations, plans, intentions and strategies, including, but not
limited to, statements regarding, molecular iodine's effect on
inhibiting fibrocystic breast tissue cell growth and promoting the
death of MCF10A cells, the lack of impact on healthy cells, and the
potential for use of molecular iodine in the treatment of symptoms
of FBC. These forward-looking statements may be identified by words
such as "plan", "expect," "anticipate," "believe," or similar
expressions that are intended to identify such forward-looking
statements. These forward-looking statements involve risks and
uncertainties, as well as assumptions, which, if they do not fully
materialize or prove incorrect, could cause our results to differ
materially from those expressed or implied by such forward-looking
statements. The risks and uncertainties include those described in
the company's filings with the Securities and Exchange Commission.
Given these risks and uncertainties, you are cautioned not to place
undue reliance on such forward-looking statements. The
forward-looking statements included in this news release are made
only as of the date hereof and the company undertakes no obligation
to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as may be required under applicable securities laws.
BioPharmX and Violet are registered trademarks of BioPharmX,
Inc.
Logo - http://photos.prnewswire.com/prnh/20150711/235327LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biopharmx-presents-research-at-cell-biology-2016-showing-how-molecular-iodine-promotes-breast-health-by-attacking-fibrocystic-breast-tissue-300371135.html
SOURCE BioPharmX Corporation